The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma. by McConnell, A T et al.
TRANSLATIONAL RESEARCH
BJD
British Journal of Dermatology
The prognostic significance and impact of the
CXCR4–CXCR7–CXCL12 axis in primary cutaneous melanoma*
A.T. McConnell,1 R. Ellis,1,2 B. Pathy,1 R. Plummer,3 P.E. Lovat1 and G. O’Boyle1,4
1Dermatological Sciences, Institute of Cellular Medicine and 3Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, U.K.
2James Cook University Hospital, Middlesbrough, U.K.
4Faculty of Applied Sciences, University of Sunderland, Sunderland, U.K.
Linked Comment: Spender and Inman. Br J Dermatol 2016; 175:1140–1141.
Correspondence
Penny E. Lovat.
E-mail: penny.lovat@ncl.ac.uk
Accepted for publication
27 April 2016
Funding sources
This work was supported by the Medical Research
Council, Cancer Research U.K. and the British
Skin Foundation.
Conflicts of interest
None declared.
P.E.L. and G.O. are joint senior authors
*Plain language summary available online
DOI 10.1111/bjd.14720
Summary
Background Expression of the chemokine receptor CXCR4 is known to regulate
melanoma metastasis to distant sites with high expression of the CXCL12 ligand.
However, the prognostic impact of CXCR4 expression and potential for
autocrine-mediated activation of prosurvival mitogen-activated protein kinase sig-
nalling remains enigmatic. Furthermore, expression of the decoy receptor CXCR7
within the local cutaneous melanoma microenvironment remains undefined.
Objectives To define the contribution and prognostic impact of CXCR4–
CXCR7–CXCL12 signalling in primary cutaneous melanomas and the immediate
tumour microenvironment.
Methods Immunohistochemical/immunofluorescent expression of CXCR4, CXCR7
or CXC12 was analysed in human metastatic melanoma cell lines, primary cuta-
neous cell types and a retrospective cohort of primary melanomas/benign naevi.
CXCL12 secretion by melanoma/cutaneous cells was evaluated by enzyme-linked
immunosorbent assay, and autocrine CXCR4–CXCL12 signalling was investigated
by addition of a CXCL12-neutralizing antibody.
Results CXCR4 expression was significantly higher in primary melanomas that subse-
quently metastasized after 7 years (P = 0037). Stratification for American Joint Com-
mittee on Cancer (AJCC) stage II disease revealed significantly decreased disease-free
survival in patients with > 50% CXCR4 expression (P = 0036), while comparative
analysis of CXCL12 expression in the adjacent epidermis of all AJCC stage melanomas
revealed increased CXCL12 correlated with prolonged time to metastasis (P = 0014).
CXCR7 was expressed within the primary melanoma microenvironment but was
absent on primary tumours. Addition of anti-CXCL12 to BRAF-mutant melanoma cells
resulted in downregulation of phospho-CXCR4 and phospho-extracellular signal-
related kinase, indicating autocrine CXCR4–CXCL12 signalling.
Conclusions CXCR4 expression defines a potential prognostic biomarker for AJCC
stage II melanoma. Moreover, targeting the CXCR4–CXCR7–CXCL12 axis may
represent a novel therapeutic strategy to prevent early melanoma progression.
What’s already known about this topic?
• CXCR4 expression is associated with poor prognostic indicators including tumour
ulceration, thickness and metastasis.
• Expression of CXCR4 is crucial in regulating melanoma chemotaxis to distant
secondary sites of metastasis with high expression of the ligand, CXCL12.
• Previous studies suggest a lack of correlation between melanoma CXCL12 expres-
sion and disease progression or BRAF mutational status.
• CXCR7 is an atypical/decoy CXCL12 receptor that may act to shape CXCL12
gradients.
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What does this study add?
• Elevated CXCR4 expression is a prognostic biomarker for AJCC stage II primary
melanomas.
• Autocrine melanoma CXCR4–CXCL12 signalling promotes hyperactivation of
prosurvival MAPK signalling.
• CXCL12 expression by stromal cells in the primary melanoma microenvironment
protects from metastasis potentially by retaining tumour cells within the cutaneous
microenvironment.
• Downregulation of melanoma CXCL12 is associated with an aggressive BRAF/NRAS
mutant phenotype.
• CXCR7 expression by cutaneous vascular endothelium and not primary melanomas
suggests a mechanism mediating tumour intravasation.
What is the translational message?
• CXCR4 expression defines a potential candidate biomarker for melanoma providing
additional prognostic information to AJCC disease staging and a means of identify-
ing high-risk patient subgroups.
• The reported role of CXCR4–CXCR7–CXCL12 chemokine signalling within the pri-
mary cutaneous melanoma microenvironment highlights the potential for targeting
this chemokine axis to prevent the development of metastatic disease.
Cutaneous melanoma is the most aggressive form of skin
cancer, with an increasing incidence worldwide. This is par-
ticularly so in younger individuals, for whom death from
metastatic disease accounts for 80% of all skin cancer
deaths. Moreover, despite recent advances in targeted thera-
pies to oncogenic BRAF/NRAS-induced prosurvival mitogen-
activated protein kinase (MAPK) signalling and novel
immunotherapies, there are still no consistently beneficial
treatments for cutaneous metastatic melanoma or reliable
biomarkers able to predict disease progression for those
patients diagnosed with seemingly low-risk, early American
Joint Committee on Cancer (AJCC) stage primary
tumours.1,2 An urgent and improved understanding of the
primary tumour microenvironment is therefore required in
order to identify credible prognostic biomarkers able to
predict those primary melanomas at greatest risk of disease
progression, and to inform the development of more effica-
cious precision-based therapeutic strategies to prevent
tumour migration and metastasis.
Chemokines and their receptors play a diverse and critical
role in normal cellular homeostasis. Principally the chemokine
system induces the directional migration of chemokine recep-
tor-expressing cells down chemokine ligand gradients, with
involvement in processes as early as embryogenesis and in
normal immune responses.3 Unsurprisingly, cancer cells may
hijack chemokine axes, upregulate chemokine receptors or
secrete chemokine ligands, directly impacting on the beha-
viour of the tumour cell itself, the tumour microenvironment
and establishment of metastasis. In this context deregulation
of CXCR4–CXCR7–CXCL12 signalling is a well-described
mechanism of tumour cell migration and metastasis.4
The gain of CXCR4 expression by melanoma cells not only
permits migration towards CXCL12 at common metastatic
sites, but may also promote tumour cell survival and prolifera-
tion through paracrine/autocrine-mediated activation of
MAPK cell signalling, highlighting a potential role for CXCR4–
CXCL12 signalling in melanomagenesis.5,6 Furthermore,
elevated CXCR4 expression has been linked to melanoma
ulceration and thickness and disease progression,7–10 although
to date CXCR4 expression as a prognostic biomarker remains
ambivalent.11 Similarly, the role of the CXCL12 chemokine
ligand within primary cutaneous melanomas has largely been
overlooked. Importantly, CXCL12 functions to shape the pri-
mary tumour infiltrate, promoting angiogenesis by recruiting
potent proangiogenic plasmacytoid dendritic cells or creating
an immunosuppressive tumour microenvironment through
recruitment of CD4+ T regulatory cells.12 However the effect
of CXCL12 within the local microenvironment of primary
cutaneous melanoma remains unexplored, with only one
study reporting an apparent correlation between the absence
of tumoral expression and poor prognosis.11
To add complexity to CXCR4–CXCL12 signalling, recent
studies have identified CXCR7 as a chemokine receptor that
binds to CXCL12 with 10-fold greater affinity compared with
CXCR4.13 However, despite its classical features as a chemo-
kine receptor, in general CXCR7 functions as a ‘decoy’ recep-
tor that ‘scavenges’ and hence removes monomeric CXCL12 to
dampen or inhibit CXCR4–CXCL12 signalling. CXCR7 also has
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the ability to heterodimerize with CXCR4, thereby potentially
modulating downstream signalling including proliferation,
survival and cell migration. Indeed, the upregulation of
CXCR7 has been shown to promote growth and migration of
a number of tumour types14–16; however, to date there are no
reports of CXCR7 expression or function in melanoma.
Although it is known to influence the metastasis of mela-
noma to distant sites, the role of CXCR4–CXCR7–CXCL12 sig-
nalling in the primary melanoma local environment and its
influence on early tumour migration and invasion remain
unclear.5
In the present study we report high levels of CXCR4 expres-
sion within primary melanomas as a novel prognostic biomar-
ker, identifying high-risk AJCC stage II tumours. We further
identify and characterize CXCL12 and CXCR7 expression
within primary melanomas and the cutaneous microenviron-
ment, highlighting a link between relative CXCL12 expression
and BRAF/NRAS mutational status and associated autocrine
signalling, and a mechanism by which the CXCR4–CXCR7–
CXCL12 axis promotes melanoma migration and metastasis.
Materials and methods
Patient demographics
Retrospective formalin-fixed paraffin-embedded (FFPE) tissue
was obtained from a cohort of 77 samples. These comprised
13 benign melanocytic naevi and 64 primary AJCC stage I, II
or III melanomas at the time of diagnosis and following
excision at the Royal Victoria Infirmary, Newcastle upon
Tyne between January 2003 and May 2005. Full ethical per-
mission was obtained (Newcastle and North Tyneside
research ethics committee, reference 08/H0906/95+5), and
all aspects of the study were performed in accordance with
the Declaration of Helsinki principles. Data were correlated
with clinical outcome after a minimum of 7 years of follow-
up, allowing the correlation of CXCR4 expression in the
primary tissue sample with the time to development of
metastatic disease (disease-free survival). Disease recurrence
was defined by the time to first radiological or tissue diagno-
sis of metastatic disease (nodal or systemic) from the point
of initial primary tumour excision, or time to death from
melanoma (melanoma-specific mortality). Reporting of the
data was performed in line with the REMARK guidelines for
prognostic biomarkers.17
Growth and maintenance of melanoma cell lines and
primary skin cells
Human metastatic melanoma cell lines CHL-1 (BRAF/NRAS
wild-type), A375, WM-164 (both BRAF V600E mutated) and
WM1361 (NRAS mutant), and EA.hy926 endothelial cell lines
were obtained from the American Type Culture Collection
(Manassas, VA, U.S.A.). They were cultured as previously
described,18,19 with authenticity of melanoma cell lines con-
firmed by melan-A expression analysis20 and using custom
TaqMan single-nucleotide polymorphism genotyping assays
(Applied Biosystems, Warrington, U.K.) to verify BRAF/NRAS
mutational status.21 Primary human epidermal keratinocytes,
dermal fibroblasts and melanocytes were isolated from redun-
dant foreskin,22 breast or abdominal skin. Primary cultures
were expanded in human keratinocyte growth supplement
EpiLife medium (Invitrogen, Paisley, U.K.), Dulbecco’s Modi-
fied Eagle’s Medium (Lonza, Vervies, Belgium) or melanocyte
254 medium (Thermo Fisher Scientific Inc., Waltham, MA,
U.S.A.). Full ethical permission for the isolation of primary
cells was obtained as described above.
Immunohistochemistry and immunofluorescence
Immunohistochemistry for the expression of CXCR4 and
CXCR7 expression in FFPE sections of naevi, primary melano-
mas or control tonsil was carried out as previously described.23
CXCR4 was detected with monoclonal anti-CXCR4 (clone
44716, 25 lg mL1 with antigen retrieval performed using
01 mol L1 Tris-HCl pH 76; R&D Systems Europe, Abingdon,
U.K.) or CXCR7 with monoclonal anti-CXCR7 (clone 11GB,
5 lg mL1 with antigen retrieval performed using 01 mol L1
Tris-HCl pH 9; Chemocentryx, San Francisco, CA, U.S.A.) over-
night at 4 °C, as previously described.23 Isotype-matched nega-
tive control antibodies were included during all staining
procedures to demonstrate antibody specificity. Images were
acquired by light microscopy with a 920 objective (Zeiss Axio
Imager; Carl Zeiss Microscopy, New York, NY, U.S.A.).
Immunofluorescence for the detection of CXCR7 and
CXCL12 was carried out on metastatic melanoma and
EA.hy926 cell lines, primary melanocytes, keratinocytes or
dermal fibroblasts seeded at 2 9 105 cells per well for 24 h
on glass coverslips, prior to fixation in ice-cold 4%
paraformaldehyde and permeabilization with 02% Triton
X-100. Immunolabelling of cells was performed with mono-
clonal anti-CXCR7 (clone 11GB, 10 lg mL1; Chemocentryx)
or polyclonal anti-CXCL12 (clone 9797, 1 lg mL1; Abcam,
Cambridge, U.K.) overnight at 4 °C and detected with Oregon
green 488 conjugated to antimouse or antirabbit IgG (Thermo
Fisher Scientific Inc.). The nuclei were counterstained with
4ʹ,6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scien-
tific Inc.).
Fluorescent double staining of primary FFPE melanoma sec-
tions with CXCL12 and melan-A (control melanocyte marker)
was performed as previously described.5 Antigen retrieval was
performed in 10 mmol L1 sodium citrate (pH 6) for 1 min
and primary CXCL12 was detected with rabbit anti-CXCL12
(clone 9797, 1 lg mL1; Abcam), or for melan-A expression
with mouse antimelan-A (clone 731, 04 lg mL1; Abcam).
Primary antibody binding was detected with Alexa Fluor 568
conjugated to antirabbit IgG (clone 175471; Abcam) or Ore-
gon green 488 conjugated to antimouse IgG (Thermo Fisher
Scientific Inc.), and the nuclei were counterstained with DAPI
1 lg mL1. Tumour sections or stained cells were finally
mounted onto glass coverslips with fluorescence mounting
medium (Vector Laboratories Inc., Burlingame, CA, U.S.A.),
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and the images captured by confocal microscopy using 940
or 920 objectives (Leica TSC SP2 UV; Leica Microsystems
GmbH, Heidelberg, Germany).
Quantification of immunohistochemical CXCR4 and
immunofluorescent CXCL12 expression
The mean percentage immunohistochemical expression of
CXCR4 positively stained cells was derived by the analysis of up
to 10 representative fields of vision using Leica QWin image
analysis software (Leica Microsystems GmbH) as previously
described.23 CXCL12 fluorescence per tumour cell (relative to
melan-A) or within the epidermis of melanoma tissue sections
(relative to DAPI) was quantified above background fluores-
cence from four or two representative images per tumour,
respectively, using ImageJ software (http://imagej.net).
Western blotting
Preparation of whole-cell lysates and Western blotting for anti-
CXCR4 (clone 2074, 01 lg mL1; Abcam), antiphospho-
CXCR4 (clone 74012, 1 : 1000; Abcam) or phospho-extracel-
lular signal-related kinase (ERK) (clone 43775, 1 : 5000; Cell
Signalling Technology, Danvers, MA, U.S.A.) and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) (loading control)
(clone 2118, 1 : 5000; Cell Signalling Technology) was per-
formed as described previously.18
Enzyme-linked immunosorbent assay for CXCL12
Human melanoma cell lines were seeded at a density of
5 9 104 cells per well in six-well plates for 72 h prior to the
analysis of CXCL12 in cell supernatants using a commercially
available enzyme-linked immunosorbent assay (ELISA) accord-
ing to the manufacturer’s instructions (Human CXCL12/SDF-1
alpha Quantikine ELISA Kit, DSA00; R&D Systems Europe).
Treatment of cells with CXCL12-neutralizing antibody
WM-164 melanoma cells were seeded at 15 9 105 cells per
well in six-well tissue culture plates 24 h prior to the addition
of 1 lg mL1 anti-CXCL12 neutralizing antibody (clone
9797; Abcam) or IgG isotype control antibody (clone
171870; Abcam) for 5–30 min before harvesting cell lysates
for Western blotting.
Statistics
CXCR4 immunohistochemical data were expressed as median
expression levels between groups. Independent group analysis
between localized and metastatic disease (eventual AJCC stage
I/II vs. eventual AJCC stage III/IV disease) was determined by
Mann–Whitney U-test. The difference between ‘high’ and
‘low’ CXCR4 expression levels for survival curve analysis was
tested using the Wilcoxon signed-rank test. Univariate and
subsequent log-rank (Mantel–Cox) survival analysis were
undertaken using R 2.15.0 (https://www.r-project.org/). The
Mann–Whitney U-test was used for analysis of CXCL12 fluo-
rescence between localized and metastatic disease (eventual
AJCC stage I/II vs. eventual AJCC stage III/IV disease) or
BRAF-mutated and wild-type melanomas, while Pearson pro-
duct moment correlation analysis was used to correlate mean
epidermal CXCL12 fluorescence with time to metastasis or
cytoplasmic CXCR4 expression. Relative densitometry of phos-
pho-CXCR4:GAPDH or phospho-ERK:GAPDH was analysed by
one-way ANOVA with Dunnett’s post hoc correction. A P value
< 0050 was considered significant throughout. All data were
analysed using the statistical software Prism 5 (GraphPad Soft-
ware, La Jolla, CA, U.S.A.).
Results
CXCR4 expression is a prognostic biomarker in cutaneous
melanoma
To assess CXCR4 expression in the context of melanoma,
CXCR4 expression levels were initially compared in vitro in a
panel of BRAF/NRAS wild-type or mutated cutaneous mela-
noma cell lines with expression in primary cutaneous melano-
cytes. Western blot analysis of total CXCR4 expression revealed
variable but consistent expression of CXCR4 in primary mela-
nocytes, as well as in cutaneous CHL-1 (BRAF/NRAS wild-
type), WM-164 (BRAF V600E mutated) and WM-1361 (NRAS
mutated) metastatic melanoma cell lines (Fig. 1a,b), but with
enhanced expression observed in all melanoma cell lines com-
pared with expression in normal melanocytes.
Next, to determine the potential for CXCR4 expression as a
prognostic biomarker for melanoma in vivo, and as a means of
identifying high-risk tumours at diagnosis, CXCR4 expression
levels were evaluated in a cohort of primary melanomas of
differing AJCC disease stage. Primary melanomas showed vari-
able expression of both cytoplasmic and nuclear CXCR4
(Fig. 1c). Comparison of total CXCR4 expression levels in
melanomas that remained localized with expression in
tumours that subsequently metastasized after 7 years of fol-
low-up (eventual AJCC stages I/II vs. stages III/IV) revealed
significantly higher median CXCR4 expression in the meta-
static cohort (561% vs. 3758%, respectively; Mann–Whitney
U-test, P = 0037) (Fig. 1d). This highlights an association
between CXCR4 upregulation and the development of meta-
static disease, and is consistent with the reported role of
CXCR4 in cancer cell migration.5
A Wilcoxon signed-rank test confirmed a differential cut-off
point of 50% CXCR4 expression as appropriate for the perfor-
mance of survival-curve analysis, where ‘high CXCR4’ expres-
sion was defined as > 50%, and ‘low CXCR4’ expression as
< 50%. Univariate analysis of mean percentage total CXCR4
expression in all AJCC stage melanomas revealed a nonsignifi-
cant decrease in disease-free survival from 655% for individu-
als expressing low CXCR4 (< 50%) to 476% in individuals
expressing high CXCR4 (> 50%) over 7 years: log-rank (Man-
tel–Cox) test, hazard ratio (HR) 199, 95% confidence interval
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(CI) 081–491, P = 013; Figure 1e. However, stratification
for AJCC stage II melanomas at diagnosis revealed that high
CXCR4 expression (> 50%) was associated with significantly
decreased disease-free survival (reduced to 308%, compared
with 737% for individuals with low, < 50%, CXCR4 expres-
sion) and patients who remained disease free over 7 years:
log-rank (Mantel–Cox) test, HR 324, 95% CI: 108–973,
P = 0036; Figure 1f. Collectively, these results highlight a
threefold increased risk of disease reoccurrence in individuals
with high total CXCR4 expression (> 50%) (Fig. 1f), further
suggesting high CXCR4 expression as a prognostic biomarker
for AJCC stage II melanomas.
Expression and secretion of CXCL12 in cutaneous
melanoma cell lines and primary cutaneous cells
To assess the role of CXCL12 in the primary tumour environ-
ment of cutaneous melanoma, initial immunofluorescence
studies for expression of CXCL12 were performed in mela-
noma cell lines, as well as in primary cells known to be pre-
sent within the local tumour microenvironment, including
primary melanocytes, keratinocytes and dermal fibroblasts.
Immunofluorescent staining for CXCL12 revealed variable
cytoplasmic expression by all cell lines and primary cells, indi-
cating that under normal and unstimulated cell-culture
(a) (b)
(c) (d)
(e) (f)
Fig 1. CXCR4 expression is a prognostic biomarker in cutaneous melanoma. (a) Representative Western blot of CXCR4 and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) loading control expression in CHL-1 (wild-type), WM-164 (BRAF V600E mutated) or WM-1361 (NRAS
mutated) human metastatic cutaneous melanoma cell lines or primary melanocytes (n = 4). (b) Densitometric analysis of CXCR4 relative to
GADPH expression. Each bar represents the mean of four replicates of CXCR4 band intensity normalized to GAPDH band intensity (CXCR4/
GAPDH) for each cell line or primary melanocytes derived from four independent donors, and is expressed relative to the mean of each individual
experiment (mean  SD, n = 4). (c) Representative immunohistochemical expression of CXCR4 in a primary American Joint Committee on
Cancer (AJCC) stage III cutaneous melanoma depicting both nuclear and cytoplasmic CXCR4 expression. Images were acquired by light
microscopy with magnification 920, scale bar = 50 lm. (d) Scatter graph representing the mean percentage of positive CXCR4-staining cells in
localized (eventual AJCC stage of disease I/II) and metastatic melanomas (eventual AJCC stage III/IV) after 7 years of follow-up. Horizontal bars
represent the median staining percentage (Mann–Whitney U-test, P = 0037). (e) Univariate analysis of mean percentage CXCR4 expression and
disease-free survival (7 years) in all AJCC stage melanomas. Vertical lines represent individual patients developing a metastasis. Log-rank (Mantel–
Cox) test, hazard ratio 199 (95% confidence interval 081–491), P = 013. (f) Univariate analysis of percentage CXCR4 expression and disease-
free survival (7 years) in AJCC stage II melanomas. A significantly increased risk of metastasis was detected in AJCC stage II tumours expressing
> 50% mean CXCR4 compared with tumours expressing < 50% mean CXCR4. Vertical lines represent individual patients developing a metastasis.
Log-rank (Mantel–Cox) test, hazard ratio 324 (95% confidence interval 108–973), P = 0036.
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conditions, CXCL12 is likely produced in situ (Fig. 2a). To
investigate CXCL12 secretion by differing cutaneous cell types,
CXCL12 was quantified in cell-culture supernatants derived
from confluent cutaneous melanoma cell lines, primary mela-
nocytes, keratinocytes and fibroblasts using a commercial
ELISA assay (Fig. 2b). Surprisingly, although all cells displayed
cytoplasmic expression of CXCL12, only CHL-1 (BRAF/NRAS
wild-type) and WM-164 (BRAF V600E mutated) melanoma
cells and dermal fibroblasts secreted detectable levels of
CXCL12 (limit of detection 156 pg mL1; Fig. 2b).
To investigate the possibility of CXCR4–CXCL12 auto-
crine cell signalling and the impact on MAPK cell sig-
nalling, a neutralizing antibody to CXCL12 or isotype
control antibody was added to WM-164 cells. Western
blotting revealed a significant reduction of phospho-
CXCR4 expression after treatment with CXCL12-neutraliz-
ing antibody for 10 or 20 min (Fig. 2c,d; one-way ANOVA
with Dunnett’s post hoc correction, P = 0001). This was
accompanied by significant inhibition of MAPK cell sig-
nalling and a concomitant reduction in the expression of
(a)
(c) (d) (e)
(b)
Fig 2. Expression and secretion of CXCL12 in cutaneous melanoma cell lines and primary cutaneous cells. (a) Representative image from three
replicate experiments for the immunofluorescent expression of CXCL12 in cutaneous metastatic melanoma cell lines (CHL-1, A375, WM-164),
primary melanocytes, keratinocytes and dermal fibroblasts. Images were acquired with negative antibody control set to no detectable fluorescence.
Green depicts CXCL12 positivity and blue shows 4ʹ,6-diamidino-2-phenylindole nuclear staining. Images were acquired by confocal microscopy
with magnification 940, scale bar = 20 lm. (b) CXCL12 (pg mL1) secretion by human metastatic cutaneous melanoma cell lines (CHL-1, WM-
164, A375, WM-1361) and primary melanocytes, keratinocytes and dermal fibroblasts. Each bar represents the mean  SD CXCL12 secretion of
three independent experiments of cell lines or from primary cutaneous cells derived from four independent donors. (c) Representative Western
blot of phospho-CXCR4 (P-CXCR4), phospho-extracellular signal-related kinase (P-ERK), total ERK and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) loading control expression in WM-164 (BRAF V600E mutated) metastatic melanoma cells treated with anti-CXCL12 neutralizing
antibody or IgG isotype control for 5, 10, 20 or 30 min; n = 3. (d) Densitometric analysis of P-CXCR4 relative to GADPH expression. Each bar
represents the mean of three replicates of P-CXCR4 band intensity normalized to GAPDH band intensity (P-CXCR4 : GAPDH), and expressed
relative to the mean of each individual experiment (mean  SD, n = 3). Statistics were acquired by one-way ANOVA with Dunnet’s post hoc
correction, **P = 0001. (e) Densitometric analysis of P-ERK relative to GADPH expression. Each bar represents the mean of three replicates of P-
ERK band intensity normalized to GAPDH band intensity (P-ERK:GAPDH), and expressed relative to the mean of each individual experiment
(mean  SD, n = 3). Statistics acquired by one-way ANOVA with Dunnet’s post hoc correction, **P = 0003.
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phospho-ERK (Fig. 2c,e; one-way ANOVA with Dunnet’s
post hoc correction, P = 0003).
Downregulation of melanoma CXCL12 is associated with
an aggressive BRAF/NRAS mutant phenotype
To investigate further the impact of CXCL12 autocrine sig-
nalling in cutaneous melanomas in situ and to determine the
expression of CXCL12 in the immediate tumour microenvi-
ronment, CXCL12 expression was evaluated in a cohort of 24
melanocytic naevi or primary melanomas of differeing AJCC
disease stage with double staining for melan-A, used as a mel-
anocytic marker (Fig. 3a).
In line with previous observations, CXCL12 expression was
detected within the dermis, localized to dermal fibroblasts,24
and interestingly was also strongly expressed by stromal cells
within the epidermis adjacent to all primary melanomas
(Fig. 4a). In contrast, tumoral CXCL12 in all AJCC stage primary
cutaneous melanomas colocalized with melan-A expression
(Fig. 3a).
Analysis of CXCL12 within primary melanomas revealed
consistent expression of CXCL12 by tumour cells, albeit at
low levels. However, expression did not vary significantly
between localized or metastatic melanomas (Fig. 3b; Mann–
Whitney U-test; P = 011). Remarkably, comparison of
CXCL12 expression with NRAS/BRAF mutational status
revealed significantly reduced CXCL12 expression in BRAF/
NRAS-mutant tumours compared with expression in wild-type
tumours (Fig. 3c; Student’s t-test; P = 0032), suggesting that
the downregulation of CXCL12 secretion may be mediated by
activation of MAPK signalling.
Increase of CXCL12 in primary cutaneous melanoma
epidermis correlates with increased time to metastasis
To explore CXCL12 expression within the epidermis of pri-
mary melanomas and any association with disease progres-
sion, CXCL12 fluorescence was also quantified in the
peritumoral adjacent epidermis of all primary melanomas
within the study cohort. The results revealed consistent
expression of epidermal CXCL12, in particular by ker-
atinocytes in the stratum corneum (Fig. 4a) in the adjacent
epidermis overlying all primary melanomas (Fig. 4b). Com-
parative analysis of epidermal CXCL12 expression in the
adjacent epidermis of all AJCC stage melanomas vs. tumour
progression further revealed a significant correlation between
increased CXCL12 expression and increased time to metasta-
sis (Fig. 4c; Pearson correlation P = 0013). This suggests
that CXCL12 within the immediate tumour microenviron-
ment limits disease metastasis. Furthermore, a significant
correlation of adjacent epidermal CXCL12 expression with
tumoral expression of cytoplasmic CXCR4 was also observed
(Fig. 4d; Pearson correlation P = 0009). This highlights a
possible relationship between CXCL12 expression in the
microenvironment and chemokine receptor activation in the
tumour, and suggests a previously undescribed intimate
relationship between microenvironmental CXCL12, mela-
noma phenotype and clinical outcome.
Expression of CXCR7 in cutaneous melanoma and the
primary tumour microenvironment
There is a paucity of studies exploring the role of CXCR7 in
melanoma biology and within the immediate cutaneous
microenvironment, given its potential effect on the CXCR4–
CXCL12 axis. To address the potential impact of CXCR7 on
this chemokine–receptor axis, immunofluorescent analysis for
the expression of CXCR7 was performed in CHL-1 or WM-
164 melanoma cell lines, or in primary melanocytes. Expres-
sion levels were compared with known CXCR7 expression
levels in control EA.hy926 endothelial cells (Fig. 5a). While
cytoplasmic CXCR7 was clearly expressed by EA.hy926 cells,
there was no apparent expression of CXCR7 by either cuta-
neous melanoma cell lines or by primary melanocytes
(Fig. 5a).
To extend these in vitro findings, CXCR7 expression was
determined in the study patient cohort, where the results
reflected the observed in vitro expression pattern. No apparent
expression of CXCR7 was evident in any primary melanoma
or benign naevus. Intriguingly, expression of CXCR7 was
clearly detectable within the tumour microenvironment of the
dermis of seven primary melanomas; specifically it was
detected on cells lining the lumen of blood vessels and capil-
laries (Fig. 5b). However, these observations did not correlate
with either AJCC disease stage or with BRAF/NRAS mutational
status (data not shown). Collectively these data suggest that
CXCR7 expressed by the cutaneous vascular endothelium may
act as a decoy receptor for CXCL12, modulating chemokine
gradients within the tumour microenvironment.
Discussion
Tumour thickness and ulceration are two components of the
AJCC melanoma staging system that currently provide the
most important prognostic information for patients diagnosed
with primary cutaneous melanomas.25 However, neither these
nor any other prognostic indicators are reliably able to iden-
tify ‘high-risk’ patients, whose tumours will eventually pro-
gress, emphasizing the acute demand for credible, novel
biomarkers with predictive accuracy of metastatic progression.
Current evidence suggests that chemokines and their recep-
tors play a critical role in many stages of cancer progression,
with the CXCR4–CXCL12 axis known to be key to melanoma
metastasis to distant secondary sites.4 However, despite reports
demonstrating an association of CXCR4 expression with
adverse clinical features,7–10 to date no studies have character-
ized the prognostic significance of CXCR4 expression in well-
powered melanoma cohorts. In contrast to previous studies,
reporting an apparent correlation of CXCR4 expression with
melanoma ulceration, increased thickness, metastasis and mor-
bidity,7–10 Mitchell et al. suggested that CXCR4 expression cor-
relates with better prognostic features, such as the absence of
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mitosis or ulceration, tumour regression and early AJCC stage
disease.11 However, data from the current study clearly
demonstrate that elevated CXCR4 expression in melanoma sig-
nificantly correlates with a metastatic phenotype. Consistently
with these findings, individuals with AJCC stage II primary
cutaneous melanomas with high CXCR4 expression (> 50%)
were threefold more likely to develop metastasis with concur-
rent reduced disease-free survival. Collectively these data
define CXCR4 expression in primary melanomas as a novel
prognostic biomarker for AJCC stage II disease, thus identify-
ing a high-risk subgroup and enabling earlier therapeutic
intervention.
Our data further show the expression of CXCL12 by mela-
noma cells and parenchymal cells within the cutaneous
microenvironment, and additionally define an autocrine sig-
nalling mechanism whereby tumoral secretion of CXCL12 is
(a)
(b)
(c)
Fig 3. Downregulation of melanoma CXCL12 is associated with an aggressive BRAF/NRAS mutant phenotype. (a) Representative image of melan-
A (green), CXCL12 (red) expression or nuclear 4ʹ,6-diamidino-2-phenylindole (blue) staining in a primary American Joint Committee on Cancer
(AJCC) stage III melanoma, including colocalization plot of melan-A and CXCL12 expression. Images were acquired with the null primary control
set to no detectable fluorescence for each channel and by confocal microscopy with magnification 920, scale bar = 150 lm. (b) Scatter graph
representing the mean of 4 high-powered fields (HPF) of CXCL12 fluorescence/expression per melanoma cell in primary localized (eventual AJCC
stage I/II disease) or metastatic melanomas (eventual AJCC stage III/IV). Horizontal bars represent the mean  SD CXCL12 fluorescence per cell.
Statistics were acquired by Student’s t-test, P = 011 (not significant). (c) Scatter graph representing the mean (4 HPF) of CXCL12 fluorescence
per cell in all primary AJCC stage BRAF/NRAS wild-type (WT) or mutant melanomas. Horizontal bars represent the mean  SD CXCL12
fluorescence per cell. Statistics acquired by Student’s t-test, P = 0032.
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(a)
(c) (d)
(b)
Fig 4. Increased CXCL12 in primary cutaneous melanoma epidermis correlates with increased time to metastasis. Representative images of blue
4ʹ,6-diamidino-2-phenylindole staining or melan-A (green) and CXCL12 (red) expression depicted in the epidermis (a) adjacent to or (b) above
an American Joint Committee on Cancer (AJCC) stage III primary melanoma tumour. Images were acquired with negative antibody control set to
no detectable fluorescence for each channel. Images were acquired by confocal microscopy with magnification 920, scale bar = 150 lm. (c)
Scatter graph representing the mean of two high-powered fields (HPF) of CXCL12 fluorescence per cell in the adjacent epidermis of eventual AJCC
stage III/IV melanomas vs. time to metastasis (months) after 7 years of follow-up. Statistics were acquired by Pearson correlation, P = 0013. (d)
Scatter graph representing the mean (2 HPF) CXCL12 fluorescence per cell in the adjacent epidermis of all AJCC stage melanomas vs. relative
tumoral CXCR4 expression. Statistics were acquired by Pearson correlation, P = 0009.
(a) (b)
Fig 5. Expression of CXCR7 in cutaneous melanoma and the primary tumour microenvironment. (a) Representative images from three replicate
experiments for the immunofluorescent expression of CXCR7 in EA.hy926 endothelial cells (positive control), metastatic melanoma cells CHL-1 or
WM-164, and primary melanocytes. Images were acquired with negative antibody control set to no detectable fluorescence. Green depicts CXCR7
positivity and blue 4ʹ,6-diamidino-2-phenylindole nuclear staining. Images were acquired by confocal microscopy with magnification 920, scale
bar = 50 lm. (b) Representative images of CXCR7 immunohistochemical expression in a cohort of primary cutaneous melanomas of differing
American Joint Committee on Cancer stage. Images depict negative CXCR7 expression in the tumour bulk of an eventual stage III primary
melanoma, and positive CXCR7 expression in capillary and blood vessels within the tumour microenvironment, or following staining with an
isotype-negative primary antibody control. Images were acquired at 920 magnification. The arrows depict positive CXCR7 staining in capillaries
and larger blood vessels. Scale bar = 50 lm.
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able to promote activation of prosurvival MAPK cell signalling.
Indeed, previous studies have illustrated CXCL12-induced acti-
vation of MAPK p44/42 (ERK1/2) and p38,26 and in the con-
text of our data they support a role for endogenous CXCL12
driving MAPK cell signalling in melanoma. To extend these
findings in situ, our data further demonstrated that there was
no significant difference in CXCL12 expression between mela-
nomas that remained localized and those that subsequently
metastasized. These results are corroborated by a previous
study also revealing a lack of any significant correlation
between CXCL12 expression and metastasis or morbidity.10
This suggests a model whereby abundant endogenous CXCL12
within the primary site would act to retain CXCR4-positive
tumour cells in situ, limiting their migration towards CXCL12-
rich distant sites. Furthermore, CXCL12 expression by primary
melanomas provides supporting evidence for autocrine
CXCR4–CXCL12 cell signalling, which as shown in our in vitro
studies promotes MAPK cell signalling, the likely consequence
of which is sustained tumour maintenance and survival.
Previous studies have not provided evidence for any associa-
tion of CXCL12 expression in melanoma with NRAS/BRAF
mutational status.11 Importantly, our data demonstrate signifi-
cantly less CXCL12 expression in BRAF/NRAS mutant melano-
mas compared with wild-type tumours. This indicates, for the
first time, an exciting potential mechanism for oncogenic
BRAF/NRAS signalling in melanomagenesis, whereby onco-
genic BRAF/NRAS signalling reduces CXCL12 expression by
primary tumour cells. Similarly, previous studies suggest that
the absence of CXCL12 expression correlates with poor clinical
outcome.11 Collectively, these and our data thus propose the
absence/downregulation of CXCL12 expression by BRAF/
NRAS primary melanomas, supporting the emergence of an
aggressive disease phenotype and an enhanced ability for
CXCR4-positive tumour cells to metastasize.
To date, the presence of CXCL12 in skin is documented11;
however, the role of CXCL12 within the tumour microenvi-
ronment and its effect on the primary tumour have not been
defined. Quantification of CXCL12 expression within the epi-
dermis revealed a positive correlation with increased microen-
vironmental CXCL12 and increased time to metastasis.
Similarly, increased tumoral cytoplasmic CXCR4 expression
correlated with increased CXCL12 expression. These data are
coherent as they suggest that tumoral CXCR4 is chronically
activated by microenvironmental CXCL12, and is therefore
internalized from the melanoma cell membrane. Importantly,
chronic CXCR4 signalling by melanoma is supported by our
in vitro observation of basal phospho-CXCR4 levels, phosphory-
lation of CXCR4 being characterized by ligand occupancy and
a prerequisite of receptor internalization.27 Moreover, our data
suggest that a high level of CXCL12 within the epidermis adja-
cent to primary melanomas may act to retain CXCR4-positive
tumour cells in situ, thereby promoting radial growth and
delaying melanoma vertical invasion into the dermis and sub-
sequent metastasis to distant sites.
CXCL12 interacts with its signalling receptor, CXCR4, and
also the atypical/scavenging receptor CXCR7, recently
redesignated ACKR3.28 CXCR7 has a powerful capacity to
scavenge CXCL12, and studies suggest that serum CXCL12
levels may be increased fivefold when CXCR7 is absent or
inhibited.29 Although CXCR7 is expressed at low levels within
the primary cutaneous melanoma microenvironment, its
observed expression by vascular endothelial cells supports pre-
vious observations of CXCR7 expression by endothelial cells in
vasculature associated with breast and lung tumour.30 This
further supports the likelihood of CXCL12 sequestration,
potentially altering chemokine gradients within the parench-
yma and facilitating melanoma intravasation. Furthermore,
although we did not observe any association between
microenvironmental CXCR7 expression and melanoma pro-
gression, other studies suggest that high CXCR7 expression is
often associated with periods of accelerated tumour growth,
hypoxia and angiogenesis.31
Overall, our data highlight a previously undescribed role
and cross-talk of the CXCR4–CXCR7–CXCL12 chemokine axis
within the primary cutaneous melanoma microenvironment,
and its intimate relationship with disease dissemination and
clinical outcome. Moreover, the definition of high CXCR4
expression as a potential novel prognostic biomarker for AJCC
stage II melanomas will enable earlier therapeutic intervention
and improved patient outcomes.
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